Having the cake and eating it? Clofazimine boosts immunotherapy while limiting side effects.
Cancer Cell
; 42(5): 738-741, 2024 May 13.
Article
em En
| MEDLINE
| ID: mdl-38579723
ABSTRACT
Combined immune checkpoint blockade (ICB) for cancer exhibits good efficacy in a subset of patients but also associates with immune-related adverse events. Xue et al. use an elegant drug screening strategy to identify the antimicrobial drug clofazimine as an agent that both potentiates ICB efficacy and decreases immune-related adverse events.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Clofazimina
/
Imunoterapia
/
Neoplasias
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article